Home » Stocks » APM

Aptorum Group Limited (APM)

Stock Price: $3.07 USD -0.12 (-3.76%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $3.46 +0.39 (12.70%) Feb 26, 7:02 PM
Market Cap 104.42M
Revenue (ttm) 535,166
Net Income (ttm) -18.69M
Shares Out 29.01M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $3.07
Previous Close $3.19
Change ($) -0.12
Change (%) -3.76%
Day's Open 3.16
Day's Range 3.03 - 3.36
Day's Volume 449,833
52-Week Range 1.16 - 14.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 1 month ago

Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug. The post APM Stock: 9 Things to Know About Aptorum as ...

Business Wire - 1 month ago

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused ...

Business Wire - 2 months ago

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical compa...

Business Wire - 2 months ago

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biop...

InvestorPlace - 3 months ago

Aptorum Group has competition in the rapid pathogen identification and detection diagnostics (RPIDD) field. Is APM stock the best bet?

InvestorPlace - 4 months ago

Aptorum Group got a boost when the company jumped into the Covid-19 conversation. APM stock looks like a late entry into crowded field.

InvestorPlace - 4 months ago

APM stock is a risky name, but the company's recent deal with Singapore has potentially given it a huge opportunity in Asia. The post Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy...

InvestorPlace - 4 months ago

APM stock remains a highly speculative bet for investors as the small biotech company comes with significant risk and volatility. The post Aptorum Group Is Risky, Despite Popularity appeared f...

Business Wire - 4 months ago

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biop...

InvestorPlace - 4 months ago

APM stock mostly flew under the radar among biotechnology investors. After a recent price surge, though, the stock is now an attention getter.

Business Wire - 4 months ago

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on n...

Business Wire - 4 months ago

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical com...

24/7 Wall Street - 4 months ago

Aptorum Group Ltd. (NASDAQ: APM) shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious di...

Benzinga - 4 months ago

Aptorum Group Ltd (NASDAQ: APM) shares are skyrocketing Tuesday following an announcement concerning the setting up of a subsidiary focused on diagnostic testing. What Happened: U.K.-based ...

InvestorPlace - 4 months ago

APM stock is soaring on news that Aptorum Group is launching a subsidiary focused on liquid biopsies for infectious diseases. The post APM Stock: Why Aptorum Group Is Soaring 500% Today appea...

Business Wire - 4 months ago

NEW YORK, LONDON, & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address gl...

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)-- #euronextlisting--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeuti...

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)-- #Euronext--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to a...

About APM

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in n... [Read more...]

Industry
Biotechnology
IPO Date
Dec 18, 2018
CEO
Chung Yuen Huen
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
APM
Full Company Profile

Financial Performance

In 2019, Aptorum Group's revenue was $535,166, an increase of 39.57% compared to the previous year's $383,450. Losses were -$18.69 million, 26.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Aptorum Group stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 323.45% from the latest price.

Price Target
$13.00
(323.45% upside)
Analyst Consensus: Strong Buy